We and othershave already demonstrated that nebivolol decreased ROS concentration by affecting thesignalling pathways leading to NADPH oxidase activation in endothelial cells [3], in experimental hyperlipidemia [37, 38] andin angiotensin II-treated rats [7]. The gene discussed is FMO5; the disease is hyperlipidemia.